VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes | Dr Cecilia Low Wang

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

Dr Cecilia Low Wang (Colorado Prevention Center, US) discusses the findings from the VOYAGER PAD - rivaroxaban in symptomatic PAD with and without comorbid diabetes study. The study assessed the efficacy and safety of rivaroxaban in patients with PAD with concomitant diabetes after lower extremity revascularization.
The study presented at ESC Congress 2021 showed that the efficacy of rivaroxaban 2.5 mg BID was consistent regardless of DM status at baseline, however a higher rate of discontinuation among these patients may have attenuated the observed benefit (ITT).

Discussion points:
Aim, patient population and endpoints
Key findings
Take-home messages for clinicians
Influence on FDA advice

Recorded remotely from Aurora, 2021.
Interviewer: Jordan Rance
Editor: Mirjam Boros

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.